Fenbendazole – LiverTox entry (NIDDK) (2026)

Peer-Reviewed Study · LiverTox, National Institute of Diabetes and Digestive and Kidney Diseases · April 20, 2026

LiverTox et al., 2026-04-20: The NIH LiverTox entry classifies fenbendazole as a probable cause of clinically apparent liver injury (likelihood score C) and advises serum enzyme testing once or twice monthly in anyone taking it.

Patients who admit taking fenbendazole should be advised to have serum enzymes tested regularly, once or twice monthly.

LiverTox et al., 2026-04-20: The NIH LiverTox entry classifies fenbendazole as a probable cause of clinically apparent liver injury (likelihood score C) and advises serum enzyme testing once or twice monthly in anyone taking it. F3 and C8. Record fields from the same entry: 'Fenbendazole is not approved for use in humans'; 'has not been shown to be effective in treating any form of cancer in humans'; 'A typical regimen is 220 mg daily four days per week'; likelihood score C; onset 'within a few days to as long as a year'. Quote is a full sentence from the Outcome and Management section. NOTE FOR THE VERIFIER: a direct fetch of this Bookshelf page returns a Google reCAPTCHA challenge page; the text was read through a rendered extractor, so an automated re-open may fail. Page is HTML, so no pdf_url and hosting is LINK despite federal authorship. Document_date is the entry's own 'References updated: 20 April 2026' line.